News

RheumaGen Awarded Grant from Colorado Office of Economic Development

RheumaGen was recently awarded a $250,000 Early-stage Capital and Retention grant from the Colorado Office of Economic Development and International Trade (OEDIT). The grant is aimed to support RheumaGen in commercializing its disruptive HLA gene editing technology for patients with refractory rheumatoid arthritis. OEDIT grants promote the growth and sustainability of advanced industries in Colorado.

Learn more here.

Contact Us

Media inquiries: RheumaGen@argotpartners.com

Dedicated to Patients in Need

RheumaGen was founded to relieve the burden that individuals suffering from autoimmune diseases have carried for so long. Mindful also of our own family members who are patients, we are not interested in incremental improvements. We seek cures; we seek remission.

Learn Our Story